Cognition Therapeutics Q1 net loss $6.2M; advances Alzheimer's and dry AMD trials

COGNITION THERAPEUTICS INC

2023-Q1 EPS reported -$0.21

Net loss $6.2M ($0.21 per share) vs $3.8M ($0.17) in Q1 2022.
Cash $38.8M; runway into H2 2024; $35M equity agreement with Lincoln Park Capital.
Completed enrollment in Phase 2 SEQUEL (Alzheimer's); topline data expected Q2 2023.
FDA cleared Phase 2 START (540 patients) for early AD and Phase 2 MAGNIFY for dry AMD.
Hired John Doyle as CFO effective May 1, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COGNITION THERAPEUTICS INC reported first quarter ended March 31, 2023 results: net income a net loss of $6.2 million, EPS $(0.21) per basic and diluted share.

Period: first quarter ended March 31, 2023
Net income: a net loss of $6.2 million
EPS: $(0.21) per basic and diluted share
Result: reported results

Exact text from the filing

The Company reported a net loss of $6.2 million, or $(0.21) per basic and diluted share for the first quarter ended March 31, 2023, compared to a net loss of $3.8 million or $(0.17) per basic and diluted share during the same period in 2022.

View on SEC.gov

Browse all earnings releases →

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-055999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.